Please login to the form below

Not currently logged in
Email:
Password:

Counterfeit medicines summit in US

Anti-counterfeiting group, the Partnership for Safe Medicines has announced it will hold its inaugural conference in October in Washington, DC

The Partnership for Safe Medicines, a coalition devoted to combating the counterfeiting of prescription drugs, has announced that it will hold its inaugural conference in October in Washington, DC.

The coalition is made up of dozens of organisations and associations, including Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organisation, the World Health Organisation (WHO), pharmacists' groups, patient organisations, and veterans' groups, among others. Sponsors of the first annual conference include Pfizer, Merck, Eli Lilly and Novartis.

The conference, which takes place at the National Press Club on October 8, will bring together leaders in academia, government and industry to explore strategies and policy recommendations aimed at combating counterfeiting.

The day will be divided into three main discussions: one on who is being harmed by counterfeiting, one on who is profiting by counterfeiting, and one on what progress has been made this year against counterfeiting. Moderators will include Dr Mary Shephard, director of the Centre for Pharmacoeconomic Studies at the University of Texas-Austin; Dr Bryan Liang, executive director of the Institute of Health Law Studies at California Western School of Law; and Tom Kubic, president of the Pharmaceutical Security Institute.

29th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Are you ready for the digital health revolution?
In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age....
#DemandDiversity: Can new medical publication guidelines help fix diversity in clinical trials?
Over the last 8 months, JAMA have been working on a new set of guidelines for research papers looking to publish with them, which is summarised in their latest editorial...
DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...

Infographics